Amid a Flurry of Biotech Deals, China Looks to Keep Innovation at Home, PharmaVoice
June 10, 2026PharmaVoice cited a Morgan Lewis LawFlash written by partner Todd Liao and associate Mudan He in an article examining China’s new regulatory pathway for advanced biomedical technologies and its potential impact on biotech innovation, licensing strategies, and cross-border life sciences partnerships.
The article discusses China’s Order 818, which establishes an alternative pathway for certain advanced therapies, including gene editing and personalized cell treatments, to reach patients more quickly. Citing the LawFlash, the publication noted that the framework could create “a ‘land domestically first’ option, reducing the pressure for Chinese innovators to license out prematurely.”
The article also highlighted Todd and Mudan’s analysis that the new pathway may require companies to revisit collaboration agreements, milestone structures, and commercialization strategies as the regulatory landscape evolves.